MT-UAVIONIX-CORPORATION
20.10.2020 12:02:07 CEST | Business Wire | Press release
Today, uAvionix Corporation announced it has filed a Technical Standard Order (TSO) application with the FAA Aircraft Certification Office (ACO) for its flagship Mode S ADS-B OUT transponder for Unmanned Aircraft Systems (UAS). The ping200X follows a line of groundbreaking, low Size, Weight, and Power (SWaP) avionics developed and certified by uAvionix for UAS and General Aviation aircraft. Approval is expected in Q4 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201020005446/en/
Weighing only 50 grams, the Level 2els Class 1 transponder packs a punch, delivering 250W of transmit power while only drawing an average of 1.5W, making its profile small enough to be fitted onto Group 1 and 2 UAS.
ping200X will be certified to TSO-C112e (Mode S), TSO-C166b (ADS-B OUT), and TSO-C88b (altitude encoder), enabling airspace access, regulatory, and Air Navigation Service Provider (ANSP) acceptance worldwide.
ping200X will be the first TSO Certified Transponder designed for the unique needs of UAS. With years of experience miniaturizing avionics for smaller, lighter, and less power consuming applications, uAvionix has made advancements to support longer flight times, higher payloads, and non-traditional aircraft designs across industries.
“Certified avionics support our customers’ needs in pursuing Type Certifications for their aircraft, gaining access to controlled airspace, or in meeting safety case objectives for Beyond Visual Line of Sight (BVLOS) operations,” said Paul Beard, CEO. “It’s a regulatory enabler, providing assurance to regulators, ANSPs, and manufacturers that the device performs as intended, while providing for safe separation for larger UAS operating in mixed-use airspace.”
Learn more at uAvionix.com/products/ping200X/ .
About uAvionix Corporation
uAvionix was founded with the mission of bringing safety solutions to the unmanned aviation industry in order to aid in the integration of Unmanned Aircraft Systems (UAS) into National Airspace Systems (NAS). uAvionix offers low SWaP TSO certified and uncertified avionics for General Aviation (GA), Airport Surface Vehicles, and the UAS markets. The team consists of an unparalleled engineering and management team with a unique combination of experience within avionics, surveillance, airport services, UAS aircraft development, radio frequency (RF), and semiconductor industries. uAvionix is backed by investors at Playground Global and Airbus Ventures.
To learn more about uAvionix manned and unmanned products, please visit: www.uavionix.com .
Follow uAvionix on Twitter: www.twitter.com/uAvionix .
Follow uAvionix on Facebook: www.facebook.com/uavionix/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201020005446/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Quaise Energy Selected for Up to $25 Million in U.S. Department of Energy Support to Advance World's First Commercial Superhot Geothermal Power Plant22.9.2026 15:30:00 CEST | Press release
Quaise's Project Obsidian, a commercial-scale superhot Enhanced Geothermal System (EGS), selected to receive federal funding as part of $99 million DOE effort to advance geothermal energy development across the United States Supports completion of the first well triplet at Project Obsidian, targeting more than 25 megawatts of gross electric power Project team includes Pacific Northwest National Laboratory, Lawrence Berkeley National Laboratory and Oregon State University Quaise Energy, a leading developer of utility-scale superhot geothermal energy, today announced that it has been selected by the U.S. Department of Energy (DOE) for up to $25 million in funding under the Next-Generation Geothermal Field Tests and Geothermal Resource Characterization and Confirmation funding opportunity. The support brings the U.S. closer to commercializing superhot Enhanced Geothermal Systems — technology that could unlock firm, clean power from hot rock beneath virtually any geography in the country.
Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 202622.9.2026 15:30:00 CEST | Press release
Late-Breaking Abstract to Feature New Data from First Phase 3 Registrational Study of Arcotatug Tavatecan in Previously Treated Advanced Gastric CancerTAK-928 Presentations Reinforce Potential in Patients with Immunotherapy-Resistant Non-Small Cell Lung Cancer (NSCLC) and Previously Untreated NSCLCTakeda Continues to Progress Clinical Development of Arcotatug Tavatecan and TAK-928; New Non-Squamous NSCLC Sub-Trial Added to Global Phase 3 MarsLight-11 Study Evaluating TAK-928 vs. Docetaxel Monotherapy Takeda(TSE:4502/NYSE:TAK)announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026, in Madrid, Spain. Key data will include a late-breaking abstract on arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343*) and two presentations on TAK-928 (Innovent R&D code: IBI363*). Clinical and real-world analyses of ALUNBRIG® (brigatinib) and FRUZAQLA® (fruquintinib) will also be
From CSR to Public Health Impact: How Colgate Bright Smiles, Bright Futures® is Driving Behavior Change for the Next Billion Children and Their Families22.9.2026 15:00:00 CEST | Press release
Colgate-Palmolive builds on its legacy of oral health, publishing an impact evaluation, evolving its health education tools rooted in behavior change, and scaling its global health partnerships. Colgate-Palmolive, the worldwide leader in oral care, announced a strategic evolution in its flagship oral health education program, Colgate Bright Smiles, Bright Futures® (BSBF), reflecting the Company’s commitment to global public health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922129016/en/ Launched in 1991, the program has reached over two billion children and their families across more than 100 countries, demonstrating how private-sector commitment designed to support communities, can become a powerful force for public health, driving healthier behaviors and positive outcomes at scale. From health education curriculum and school programming to mobile dental vans and free oral health screenings, BSBF helps children and
Citi Wealth’s 2026 Global Family Office Report Reveals Clients Are Shifting Their Focus Towards Public Equities While Becoming More Deliberate and Resilient Amid Uncertainty22.9.2026 14:30:00 CEST | Press release
Public equities have re-emerged as the primary destination for incremental capital Private markets remain a strategic pillar of family office portfolios Artificial intelligence is moving from experimentation toward implementation Cross-border complexity is rising as families become increasingly international Leadership succession and next-generation preparedness are now immediate priorities rather than distant considerations Watch Citi Wealth’s Global Family Office leadership discuss the report’s findings here. Citi Wealth today released its 2026 Global Family Office Report, offering an inside perspective into the thinking and behaviors of the world’s most sophisticated investors. The report was compiled by Citi Wealth’s Global Family Office Group, which works with more than 1,900 family offices worldwide. Conducted in June and July 2026, the survey sheds light on how over 350 family offices in more than 40 countries are navigating new complexities in an era defined by uncertainty. Tod
Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio22.9.2026 14:30:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that data from across its Inflammation and Autoimmunity (IAI) portfolio will be presented at the European Academy of Dermatology and Venereology (EADV) 2026, held September 30 - October 3, 2026, in Vienna, Austria. "The breadth of research being presented at EADV 2026 highlights the strength of our Inflammation and Autoimmunity portfolio," said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Data presentations in hidradenitis suppurativa, atopic dermatitis and prurigo nodularis demonstrate our commitment to advancing innovation across immune-mediated skin diseases and deepening our understanding of the patient experience." Details on key Incyte data presentations at EADV include: Oral Presentations Atopic Dermatitis Atopic Dermatitis and Life Course Disruption: Evidence From a Multidimensional International Survey (TOPiQAL) (Session: Free Communication 1: Atopic dermatitis/Eczema. Thursday, October 1, 2:50-3:0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom